{"id":413,"date":"2024-02-14T19:19:51","date_gmt":"2024-02-14T19:19:51","guid":{"rendered":"https:\/\/www.merckvaccines.com\/capvaxive\/?page_id=413"},"modified":"2026-03-26T15:21:17","modified_gmt":"2026-03-26T15:21:17","slug":"home","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/capvaxive\/","title":{"rendered":"CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) for Health Care Professionals"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
<\/div>\"\"
Actor Portrayal<\/div><\/div><\/picture>

A PCV specifically designed for adults that helps protect against the serotypes responsible for the most cases of adult IPD<\/strong>1,2,a<\/strong><\/sup>

THAT’S BRILLIANT DESIGN<\/strong><\/mark><\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n

Percentage of IPD cases caused by serotypes covered by CAPVAXIVE vs PCV20 among adults aged 50+ years at a national level1,2,a,b<\/sup><\/strong><\/p><\/div><\/div><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n\n
\"~54%<\/figure><\/div><\/div>\n\n\n\n

% of IPD cases in adults 50+ covered by vaccine serotypes<\/strong><\/p><\/div><\/div><\/p>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n

\n
<\/div>\n\n\n\n

CAPVAXIVE is the only FDA-approved pneumococcal conjugate vaccine that helps protect against serotypes<\/a><\/mark><\/strong> responsible for ~82%<\/strong> of invasive pneumococcal disease cases in adults 50 years or older, compared to ~54%<\/strong> by PCV20 on a national level.1,2,a<\/sup> Learn more >><\/a><\/strong><\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
<\/div>\n\n\n\n\n

Intentional serotype selection<\/strong>1,2,b<\/strong><\/sup><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

CAPVAXIVE is specifically designed to help protect against the serotypes responsible for the most cases of adult IPD.<\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

11 serotypes in CAPVAXIVE<\/strong><\/mark>
that are not covered by PCV20 cause
~37% of IPD cases<\/strong><\/mark>
in adults 50 years or older at a national level.<\/p><\/div><\/div>\n<\/div>\n\n\n\n

\n
\"\"\"\"<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

9 serotypes in PCV20<\/strong>
that are not covered by CAPVAXIVE cause
~8% of IPD cases<\/strong>
in the same age group.<\/p><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines.2<\/sup> There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20.<\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

Quick links:<\/strong><\/p><\/div><\/div><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n\n

CDC recommendations<\/strong><\/h3>
\n\n

Recommended for adults aged 50 or older3<\/sup><\/p><\/div><\/div><\/p>\n\n<\/div>

CDC recommendations<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n

Dosing and administration<\/strong><\/h3>
\n\n

1 dose for all your appropriate adult patients<\/p><\/div><\/div><\/p>\n\n<\/div>

Dosing and administration<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n

Reimbursement<\/strong><\/h3>
\n\n

Covered for ~99% of commercial medical lives4<\/sup><\/p><\/div><\/div><\/p>\n\n<\/div>

Reimbursement<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

CDC recommendations: updated October 20243<\/sup><\/mark><\/strong><\/p><\/div><\/div><\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n
\"CAPVAXIVE\"CAPVAXIVE<\/figure><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

 *<\/sup>Routine if PCV13 was administered at any age and PPSV23 was administered before age 65 with the last pneumococcal vaccine being at least 5 years prior. Shared clinical decision-making if PCV13 was administered at any age and PPSV23 was administered at or after the age of 65 and the last pneumococcal vaccine was at least 5 years prior.3<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

 \u2020<\/sup>Certain chronic medical conditions (eg, diabetes, chronic heart disease, chronic lung disease, or chronic liver disease) or behavioral risk factors (eg, smoking or alcoholism).3<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

 \u2021<\/sup>See ACIP recommendations for full list of immunocompromising conditions, including HIV.3<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

 \u00a7<\/sup>Also applies to patients with certain immunocompromising conditions who have received PCV13 followed by 2 doses of PPSV23.3<\/sup><\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
\n
\n
\"\"\/<\/picture><\/figure><\/div>

Are my adult patients at risk?<\/mark><\/h2>
\n

Learn about the burden of disease and how your patients might be affected.<\/p>\n\n\n\n

\n\n\n
Read about the burden<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n\n
\n\n
\n
<\/div>\n\n\n\n